Welcome to Health Economics Course Webpage

Chung KC, Walters M, Greenfield ML, Chernew ME. Endoscopic versus open carpal tunnel release: a cost-effectiveness analysis. Plastic and Reconstructive Surgery 1998, 102(4), 1089-1099.

Vasen AP, Neptune NJ, Kuntz KM, Simmons BP, Katz JN. Open versus endoscopic carpal tunnel release: a decision analysis. Journal of Hand Surgery 1999, 24A, 1109-117.

Lejeune et al. (2005) (TreeAge); Parameters (excel)

Reference: Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. Journal of Nuclear Medicine 2005 46(12):2020-2028.

Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastro-esophageal reflux disease, Medical Decision Making 2002; 22: 290-308.

TreeAge model (from authors’ website)

Markov Model Basics (Handout)

Example Gray et al, Ch. 9 (TreeAge Model)

HIV Example Drummond et al, Ch. 9 (excel)

HIV Example Drummond et al, Ch. 9 (TreeAge Model)

Rao C, Darzi A, Athanasiou T 2011, Practical examples of the application of decision analysis in healthcare, Evidence Synthesis in Healthcare: A Practical Handbook for Clinicians, Editor(s): Darzi, Athanasiou, Berlin Heidelberg, Springer-Verlag, Pages:221-267.

MVR Slides

Briggs and Sculpher Paper (Handout)

Briggs and Sculpher (1998) (TreeAge Model – No discount)

Briggs and Sculpher (TreeAge Model – half-cycle correction + @3.5% discount)

Briggs and Sculpher (TreeAge Model – half-cycle correction + @3.5% discount + PSA)

Background literature on how to glean probabilities from the Clinical/Epidemiological studies:

Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics 2007;25(1):3-6.

Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrobial Agents and Chemotherapy 2004 Aug;48(8):2787-92.

Moser BK, McCann MH. Reformulating the hazard ratio to enhance communication with clinical investigators. Clinical Trials 2008;5(3):248-252.

Buyse M. Reformulating the hazard ratio to enhance communication with clinical investigators. Clinical Trials 2008;5(6):641-642.

Ishak KJ, Kreif N, Benedict A, Muszbek N. Overview of parametric survival analysis for health-economic applications. Pharmacoeconomics. 2013 Aug;31(8):663-75.

Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Medical Research Methodology 2011 Oct 10;11:139. (Note: the authors supplied an excel sheet)

Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Medical Research Methodology 2012 Feb 1;12:9. (Note: the authors provide their R codes)

Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics 2014 Feb;32(2):101-108. (Note: authors supplied their digitized data and approximate survival data based on the algorithm of Guyot et al., 2014)

Time-to-Event Analysis

Weibull Transition Probability

Extracting data from KM curves:

Example Data SAS syntax STATA syntax

Hoyle and Henley Paper: Excel Sheet

Diaby et al. (2014) – IPD Algorithm R Syntax

Arm1Data: First file Second file IPD1; Arm2Data: First file Second file IPD2; Combined IPD STATA syntax

Cost Analysis

Some Examples of Costing:

Wolstenholme J, Rivero-Arias O, Gray A, Molyneux AJ, Kerr RS, Yarnold JA, Sneade M; International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group. Treatment pathways, resource use, and costs of endovascular coiling versus surgical clipping after aSAH. Stroke 2008 Jan;39(1):111-9. Appendix

Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Medicine 2003, 20(6):442-50. Excel Calculator

Goeree R, Lim ME, Hopkins R, Blackhouse G, Tarride J-E, Xie F, O’Reilly D. Prevalence, total and excess costs of diabetes and related complications in Ontario, Canada. Canadian Journal of Diabetes 2009;33(1):35-45.

Statistical Analysis of Costs:

STATA Syntax Details at http://www.uphs.upenn.edu/dgimhsr/eeinct.htm

Equity in Economic Evaluation

TreeAge Lab Sessions: